Korean J Hematol.  2006 Dec;41(4):243-249. 10.5045/kjh.2006.41.4.243.

The Correlation between G-CSF Dosage and the Number of Collected CD34+ Cells in Pediatric Patients Undergoing Peripheral Blood Stem Cell Mobilization

• Lee JS
• Jung HJ
• Park JE

• KMID: 2305210
• DOI: http://doi.org/10.5045/kjh.2006.41.4.243

Abstract

BACKGROUND: In high risk malignancies of pediatric patients, many investigators have explored the use of stronger myeloablative regimens with autologous peripheral blood stem cell rescue such as the Tandem protocol. As the collection of peripheral blood stem cells in children have many risks, it is important to achieve the maximum number of CD34+ cells per leukapheresis. We analyzed the use of different doses of granulocyte-colony stimulating factor during a mobilization for an increased number of CD34+ cells.
METHODS
A retrospective chart review was performed for 31 patients undergoing autologous peripheral blood stem cell mobilization. All patients had received specific chemotherapies. At the nadir, each patient was injected with 5 microgram/kg/day G-CSF. When the level of white blood cells reached more than 1,000/microliter, patients were divided according to the different dose of G-CSF that was given per day: Group I, 5 microgram/kg, Group II, 10 microgram/kg, Group III, 15 microgram/kg. After 2~3 days, leukapheresis was performed, and then the number of CD34+ cells and other cells were counted.
RESULTS
In group III, the number of collected CD34+ cells was 19.86+/-14.45x10(6)/kg and significantly higher than in the other two groups. Also, group III had significantly higher numbers of total nucleated cell, mononucleated cells, white blood cells, though the absolute neutrophil count compared with the other groups. There were no serious adverse effects associated with the higher G-CSF doses employed.
CONCLUSION
At nadir, a pediatric patient received 5 microgram/kg G-CSF daily until the WBC count reached more than 1,000/ microliter. If the patient is injected with 15 microgram/kg/day of G-CSF, we can achieve a more sufficient CD34+ cell yield with one leukapheresis, safely.

Keyword

Peripheral blood stem cell transplantation; Mobilization; G-CSF; CD34+ cell

MeSH Terms

Child
Drug Therapy
Granulocyte Colony-Stimulating Factor*
Hematopoietic Stem Cell Mobilization*
Humans
Leukapheresis
Leukocytes
Neutrophils
Peripheral Blood Stem Cell Transplantation
Research Personnel
Retrospective Studies
Stem Cells*
Granulocyte Colony-Stimulating Factor

Reference

1). Grupp SA., Stern JW., Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol. 2000. 18:2567–75.

2). Kletzel M., Katzenstein HM., Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol. 2002. 20:2284–92.

3). Kunihiko T., Hitoshi O. PBSC mobilization. Transfus Apher Sci. 2004. 31:233–43.

4). Ramakrishna LR. Mobilization and collection of peripheral blood progenitor cells for transplantation. Tansfus Apher Sci. 2005. 32:63–72.

5). Lee MA., Lee S., Seong CM., Chung WS. The absolute number of CD34+ cells predicts optimal timing of progenitor cell collection and posttransplant hematopoietic recovery. Korean J Clin Pathol. 2000. 20:103–9.

6). Lie AK., Hui CH., Rawling T, et al. Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF. Bone Marrow Transplant. 1998. 22:853–57.

7). Haut PR., Cohn S., Morgan E, et al. Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients. Biol Blood Marrow Transplant. 1998. 4:38–42.

8). Nademanee A., Sniecinski I., Schmidt GM, et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol. 1994. 12:2176–86.

9). Weaver CH., Birch R., Greco FA, et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol. 1998. 100:338–47.

10). Demirer T., Ayli M., Ozcan M, et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol. 2002. 116:468–74.

11). Ham TY., Kim JH., Won SC., Lyu CJ. Predictive parameters for mobilized peripheral blood CD34+ progenitor cell collection in pediatric patients. Korean J Hematol. 2003. 8:31–6.

12). Bensinger W., Appelbaum F., Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995. 13:2547–55.

13). Majado MJ., Gonzalez C., Marin L., Morales A., Moya MR., Candel R. Second mobilization of peripheral blood progenitor cells in patients with poor first mobilization. Transplant Proc. 2003. 35:2027–8.

14). Lefrere F., Levy V., Makke J., Audat F., Cavazzana-Calvo M., Miclea JM. Successful peripheral blood stem cell harvesting with granulocyte colony-stimulating factor alone after previous mobilization failure. Haematologica. 2004. 89:1532–4.

15). Kroger N., Renges H., Sonnenberg S, et al. Stem cell mobilisation with 16μg/kg vs 10μg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant. 2002. 29:727–30.

16). Engelhardt M., Bertz H., Afting M., Waller CF., Finke J. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselec-tion. J Clin Oncol. 1999. 17:2160–72.

17). Grigg AP., Roberts AW., Raunow H, et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulation factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood. 1995. 86:4437–45.